A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

NCT00498407 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Colorectal Cancer
Colorectal Cancer

Interventions

DRUG: CP-4055

Sponsor

Clavis Pharma